This finding may be due to the greater tumour load and inflammatory burden of patients with advanced cancer, which is more prone to tumour-cell proliferation and invasion and tumour neovascularisation, leading to changes in the proportion of CEA, neutrophils, and lymphocytes. Here, CEACAM5 is linked to cancer.